Kerry Canady, DO
Pulmonary Disease · Clive, IANPI 1225207749
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in IA, where the typical reported total is $578.
Across 8 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$34
- Resmed Corp$32
- Verona Pharma, Inc.$21
- Axsome Therapeutics, Inc.$20
- Avadel CNS Pharmaceuticals, LLC$18
- Lilly USA, LLC$16
- plus $30 from 2 others
What the payments were for
- Food & beverage$173100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $34 |
| Resmed Corp | 1 | $32 |
| Verona Pharma, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$173 in reported general payments places this provider in the 35th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $11,581 |
| XareltoRivaroxaban | 11 | $4,014 |
| Metoprolol Succinate | 22 | $501 |
| Gabapentin | 18 | $422 |
| ClopidogrelClopidogrel Bisulfate | 17 | $294 |
| Amlodipine Besylate | 30 | $256 |
| Sertraline Hcl | 18 | $248 |
| Tamsulosin Hcl | 11 | $231 |
| Hydralazine Hcl | 15 | $120 |
| Cefdinir | 14 | $120 |
| Levothyroxine Sodium | 12 | $97 |
| Potassium Chloride | 13 | $93 |
| Azithromycin | 15 | $56 |
| Prednisone | 26 | $44 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Clive
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
- John SouthardCouncil Bluffs$184K
- Dustin McCannWest Des Moines$67K
- Alejandro ComellasIowa City$54K
- Matthew TrumpWest Des Moines$41K
- Brian WittDavenport$19K
- Shrey VelaniDes Moines$18K
- James MallenWest Des Moines$16K
- Neil HorningDes Moines$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.